| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1028941572 |
| P356 | DOI | 10.1186/1472-6874-8-22 |
| P932 | PMC publication ID | 2605606 |
| P698 | PubMed publication ID | 19038018 |
| P5875 | ResearchGate publication ID | 23501800 |
| P50 | author | Santiago Palacios | Q6121075 |
| P2860 | cites work | Peripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease: the Heart and Estrogen/Progestin Replacement Study. | Q50666815 |
| Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. | Q51802491 | ||
| Efficacy on climacteric symptoms and safety of low dose estradiol transdermal matrix patches. A randomized, double-blind placebo-controlled study | Q57010763 | ||
| Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women | Q57989064 | ||
| Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium | Q69682738 | ||
| Long-term fracture prediction by bone mineral assessed at different skeletal sites | Q72646417 | ||
| Relevant results of the WHI study for the management of the menopause in Spain | Q78889691 | ||
| Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study | Q80166265 | ||
| Guidelines for hormone treatment of women in the menopausal transition and beyond | Q81594633 | ||
| Hormone replacement therapy for preventing cardiovascular disease in post-menopausal women | Q24244146 | ||
| Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes | Q24246213 | ||
| Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | Q27860743 | ||
| Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate | Q33949094 | ||
| Estrogen plus progestin and the risk of coronary heart disease | Q34220432 | ||
| Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial | Q34266403 | ||
| Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. | Q34615300 | ||
| Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women | Q34803319 | ||
| Low-dose estrogen therapy for menopausal women: a review of efficacy and safety | Q35572578 | ||
| Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of The North American Menopause Society | Q35951378 | ||
| Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: a review of randomized clinical trials. | Q36086159 | ||
| Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism | Q36584219 | ||
| Androgens and female sexual function | Q36763335 | ||
| Comparative effects of dydrogesterone and medroxyprogesterone acetate in critical areas: the brain and the vessels | Q36974411 | ||
| Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg. | Q37196248 | ||
| Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy | Q39371857 | ||
| Initial 17beta-estradiol dose for treating vasomotor symptoms | Q39430899 | ||
| The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women | Q40379806 | ||
| The demography of menopause | Q41059426 | ||
| Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. The Menopause Study Group. | Q43536317 | ||
| Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women | Q43805532 | ||
| Lipid profiles and endothelial function with low-dose hormone replacement therapy in postmenopausal women at risk for coronary artery disease: a randomized trial | Q44454497 | ||
| Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial | Q46465794 | ||
| Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder | Q46598434 | ||
| Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial | Q46618574 | ||
| Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women | Q46863019 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | menopause | Q177708 |
| estrogen replacement therapy | Q76285049 | ||
| Hormone Replacement Therapy | Q108667313 | ||
| P304 | page(s) | 22 | |
| P577 | publication date | 2008-11-27 | |
| P1433 | published in | BMC Women's Health | Q15762590 |
| P1476 | title | Advances in hormone replacement therapy: making the menopause manageable | |
| P478 | volume | 8 |
| Q37673312 | Antiosteoporotic Activity of Genistein Aglycone in Postmenopausal Women: Evidence from a Post-Hoc Analysis of a Multicenter Randomized Controlled Trial. |
| Q89993571 | Cardiovascular Risk/Benefit Profile of MHT |
| Q47337372 | Cinnamomum burmanini Blume increases bone turnover marker and induces tibia's granule formation in ovariectomized rats. |
| Q28066699 | Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy |
| Q39216291 | Determination of the use of complementary and alternative medicine by women in the climacteric period in the Turkish city of Samsun. |
| Q36516411 | Effect of hormone replacement therapy (HRT) on periodontal status of postmenopausal women |
| Q42487188 | Effect of prolonged use of high dose of tibolone on the vagina of ovariectomized rats |
| Q58702579 | Effects of the Hormone Replacement Therapy and of Soy Isoflavones on Bone Resorption in Postmenopause |
| Q35544309 | Effects of the combined extracts of Herba Epimedii and Fructus Ligustri Lucidi on bone mineral content and bone turnover in osteoporotic rats |
| Q34748161 | Efficacy of biorhythmic transdermal combined hormone treatment in relieving climacteric symptoms: a pilot study |
| Q43058335 | Erythrina variegata extract exerts osteoprotective effects by suppression of the process of bone resorption |
| Q51442590 | Estrogen promotes B cell activation in vitro through down-regulating CD80 molecule expression. |
| Q36067442 | Research resource: nuclear receptor atlas of human retinal pigment epithelial cells: potential relevance to age-related macular degeneration |
| Q46830110 | Somatic-vegetative Symptoms Evolution in Postmenopausal Women Treated with Phytoestrogens and Hormone Replacement Therapy |
| Q39711555 | Study of the mechanisms by which Sambucus williamsii HANCE extract exert protective effects against ovariectomy-induced osteoporosis in vivo. |
| Q36246863 | Therapeutic Effects of Cortex acanthopanacis Aqueous Extract on Bone Metabolism of Ovariectomized Rats |
Search more.